Menu
Back to User profile » Prof. Dr. Roland Buhl
Papers published by Prof. Dr. Roland Buhl:
Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study)
Korn S, Milger K, Skowasch D, Schulz C, Mohrlang C, Wernitz M, Paulsson T, Hennig M, Buhl R
Journal of Asthma and Allergy 2023, 16:541-552
Published Date: 11 May 2023
Real-World Treatment of Patients Newly Diagnosed with Chronic Obstructive Pulmonary Disease: A Retrospective German Claims Data Analysis
Buhl R, Wilke T, Picker N, Schmidt O, Hechtner M, Kondla A, Maywald U, Vogelmeier CF
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:2355-2367
Published Date: 22 September 2022
Costs and Clinical Consequences of Compliance with COPD GOLD Recommendations or National Guidelines Compared with Current Clinical Practice in Belgium, Germany, Sweden, and the United States
Sethi S, Wright A, Hartgers-Gubbels ES, Hechtner M, Clark B, Wright C, Langham S, Buhl R
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:2149-2160
Published Date: 7 September 2022
Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
Kayser MZ, Drick N, Milger K, Fuge J, Kneidinger N, Korn S, Buhl R, Behr J, Welte T, Suhling H
Journal of Asthma and Allergy 2021, 14:863-871
Published Date: 12 July 2021
Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma
Drick N, Milger K, Seeliger B, Fuge J, Korn S, Buhl R, Schuhmann M, Herth F, Kendziora B, Behr J, Kneidinger N, Bergmann KC, Taube C, Welte T, Suhling H
Journal of Asthma and Allergy 2020, 13:605-614
Published Date: 11 November 2020
A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Study Protocol
Buhl R, Dreher M, Korn S, Taube C, Stock C, Zehendner CM, Kondla A, Vogelmeier CF
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:2601-2608
Published Date: 22 October 2020
Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD
Andreas S, McGarvey L, Bothner U, Trampisch M, de la Hoz A, Fležar M, Buhl R, Alter P
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:1935-1944
Published Date: 10 August 2020
Assessment of physical functioning and handling of tiotropium/olodaterol Respimat® in patients with COPD in a real-world clinical setting
Steinmetz KO, Abenhardt B, Pabst S, Hänsel M, Kondla A, Bayer V, Buhl R
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:1441-1453
Published Date: 4 July 2019
Future perspectives of anticholinergics for the treatment of asthma in adults and children
Buhl R, Hamelmann E
Therapeutics and Clinical Risk Management 2019, 15:473-485
Published Date: 14 March 2019
New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology
D'Urzo AD, Cazzola M, Hanania NA, Buhl R, Maleki-Yazdi MR
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:2805-2819
Published Date: 7 September 2018
Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study
Buhl R, Criée C, Kardos P, Vogelmeier CF, Kostikas K, Lossi NS, Worth H
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:2557-2568
Published Date: 24 August 2018
Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies
LaForce C, Derom E, Bothner U, Kloer IM, Trampisch M, Buhl R
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:1819-1831
Published Date: 1 June 2018
Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease
Bai C, Ichinose M, Lee SH, Lee KH, Jöns O, Bothner U, Zhao Y, Buhl R
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:3329-3339
Published Date: 20 November 2017
“Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD
Vogelmeier C, Worth H, Buhl R, Criée C, Lossi NS, Mailänder C, Kardos P
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:487-494
Published Date: 1 February 2017
Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age
Ferguson GT, Karpel JP, Clerisme-Beaty E, Grönke L, Voß F, Buhl R
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:2701-2710
Published Date: 31 October 2016
A year in the life of German patients with COPD: the DACCORD observational study
Buhl R, Criée CP, Kardos P, Vogelmeier C, Lossi N, Mailänder C, Worth H
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:1639-1646
Published Date: 20 July 2016
Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study
Sauer R, Hänsel M, Buhl R, Rubin RA, Frey M, Glaab T
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:891-898
Published Date: 27 April 2016
Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]
Buhl R, Banerji D
International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:287-288
Published Date: 19 March 2014
Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD
Buhl R, Banerji D
International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:729-741
Published Date: 26 October 2012